Acorda Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

Fri Dec 28, 2012 7:00am EST

* Reuters is not responsible for the content in this press release.

ARDSLEY, N.Y.--(Business Wire)--
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D.,
President & CEO, will present at the upcoming 31st Annual J.P. Morgan Healthcare
Conference on Monday, January 7, 2013 at 11:00 a.m. Pacific Time at the Westin
St. Francis Hotel in San Francisco, CA. 

A live audio webcast of the presentation can be accessed under "Investor Events"
in the Investor section of the Acorda website at or you may use
the link:

Please log in 5 minutes before the scheduled time of the presentation to ensure
a timely connection. An archived version of the webcast will be available until
February 7, 2013 on the Acorda website in the Investor Relations section. 

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies
that restore function and improve the lives of people with MS, spinal cord
injury and other neurological conditions. 

Acorda markets AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, in the
United States as a treatment to improve walking in patients with multiple
sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA
is marketed outside the United States as FAMPYRA® (prolonged-release fampridine
tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and
FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited. 

The Company also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride) and
Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda
also receives sales royalties on tizanidine hydrochloride capsules, an
authorized generic version of ZANAFLEX CAPSULES distributed by Watson
Pharmaceutics, Inc. under its agreement with Acorda. 

Acorda has an industry-leading pipeline of novel neurological therapies. The
Company is developing Diazepam Nasal Spray for treatment of certain epileptic
seizures. It is also studying AMPYRA to improve a range of functional
impairments caused by MS, as well as its use in other neurological conditions,
including cerebral palsy and post-stroke deficits. In addition, Acorda is
developing clinical stage compounds AC105 for acute treatment of spinal cord
injury and GGF2 for treatment of heart failure. GGF2 is also being investigated
in preclinical studies as a treatment for neurological conditions such as stroke
and spinal cord injury. Additional development programs include rHIgM22, a
remyelinating monoclonal antibody for the treatment of MS, and chondroitinase,
an enzyme that encourages nerve plasticity in spinal cord injury. 

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, regarding management's expectations, beliefs,
goals, plans or prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual results to differ
materially, including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not reimburse for
the use of Ampyra or our other products at acceptable rates or at all and may
impose restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of Ampyra or
from our other research and development programs, including Diazepam Nasal Spray
("DZNS") or any other acquired or in-licensed programs; we may not be able to
complete development of, obtain regulatory approval for, or successfully market
DZNS or other products under development; the occurrence of adverse safety
events with our products; delays in obtaining or failure to obtain regulatory
approval of or to successfully market Fampyra outside of the U.S. and our
dependence on our collaboration partner Biogen Idec in connection therewith;
competition, including the impact of generic competition on Zanaflex Capsules
revenues; failure to protect our intellectual property, to defend against the
intellectual property claims of others or to obtain third party intellectual
property licenses needed for the commercialization of our products; failure to
comply with regulatory requirements could result in adverse action by regulatory
agencies; and the ability to obtain additional financing to support our
operations. These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission. Acorda
Therapeutics may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue reliance on
these statements. Forward-looking statements made in this press release are made
only as of the date hereof, and Acorda Therapeutics disclaims any intent or
obligation to update any forward-looking statements as a result of developments
occurring after the date of this press release.

Acorda Therapeutics
Jeff Macdonald, 914-326-5232

Copyright Business Wire 2012
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.